1. 1711. In Vitro Activity of Cefiderocol Against US Achromobacter spp. and Burkholderia spp. Clinical Isolates from the SENTRY Surveillance Program 2020-2021. (15th December 2022) Authors: Takemura, Miki; Shortridge, Dee; Slover, Christine M; Longshaw, Christopher M; Echols, Roger; Echols, Roger; Echols, Roger; Yamano, Yoshinori Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1715. In Vitro Antibacterial Activity of Cefiderocol against Difficult-to-treat Resistant (DTR) Gram-negative Pathogens in United States from SENTRY Antimicrobial Surveillance Program in 2020/2021. (15th December 2022) Authors: Yamano, Yoshinori; Takemura, Miki; Shortridge, Dee; Slover, Christine M; Longshaw, Christopher M; Echols, Roger; Echols, Roger; Echols, Roger Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1734. Susceptibility of Cefiderocol between US Census Regions against Gram-Negative Organisms collected from the SENTRY Surveillance Program: 2020-2021. (15th December 2022) Authors: Kung, Frank H; Nguyen, Sean; Slover, Christine M; Shortridge, Dee; Streit, Jennifer M; Echols, Roger; Echols, Roger; Echols, Roger; Takemura, Miki; Yamano, Yoshinori Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗